Patients on anifrolumab spent more time in remission and low disease activity, and reached those states more quickly, vs. placebo. Achieving these states can stave off permanent organ damage.

After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn ... Lupus is an autoimmune disease in which the immune system attacks healthy tissue in the body instead ...

Overall, the trials showed that a once-monthly intravenous dose of anifrolumab was able to reduce disease activity across organ system in SLE, including skin and joints, and also helped patients ...